John Sourbeer
Stock Analyst at UBS
(0.55)
# 4,156
Out of 5,161 analysts
44
Total ratings
33.33%
Success rate
-20.45%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $8.01 | +56.05% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $121.50 | -1.23% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $238.25 | +49.00% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $41.21 | +15.55% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $105.38 | +127.75% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $15.21 | +54.50% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $18.02 | +149.72% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.35 | +48.15% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $477.72 | +0.48% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $36.81 | +177.10% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $20.46 | +144.38% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $110.25 | +16.10% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $8.01
Upside: +56.05%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $121.50
Upside: -1.23%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $238.25
Upside: +49.00%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $41.21
Upside: +15.55%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $105.38
Upside: +127.75%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $15.21
Upside: +54.50%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $18.02
Upside: +149.72%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.35
Upside: +48.15%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $477.72
Upside: +0.48%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $36.81
Upside: +177.10%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $20.46
Upside: +144.38%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $110.25
Upside: +16.10%